Literature DB >> 2165139

The JH2604 deletion variant of herpes simplex virus type 2 (HG52) fails to produce necrotizing encephalitis following intracranial inoculation of mice.

M Y Taha1, S M Brown, G B Clements, D I Graham.   

Abstract

The pathological changes and distribution of virus antigen in mouse brains were studied following intracranial inoculation of 3 week old BALB/c mice with the herpes simplex virus (HSV) type 2 strain HG52 and its deletion variant JH2604. The variant JH2604 failed to produce necrotizing encephalitis compared to the parental HG52. The morphological changes induced in JH2604-infected brains consisted of localized perivascular cuffing by lymphocytes and infiltration by immune cells. Immunohistochemical studies using polyclonal anti-HSV serum showed that JH2604 antigens were localized at the site of inoculation with no evidence of neuronal involvement. Wild-type HSV-infected brains demonstrated a wide distribution of antigens both in neuronal and supporting cells. These data provide evidence that the non-neurovirulent phenotype of JH2604 is due to inability to replicate within neuronal cells of the central nervous system and pinpoints a precise role for the HG52 sequences contained within the 1488 bp subfragment of TRL/IRL deleted in JH2604.

Entities:  

Mesh:

Year:  1990        PMID: 2165139     DOI: 10.1099/0022-1317-71-7-1597

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  2 in total

1.  Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models.

Authors:  R J Whitley; E R Kern; S Chatterjee; J Chou; B Roizman
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

2.  ICP34.5 mutants of herpes simplex virus type 1 strain 17syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures.

Authors:  C A Bolovan; N M Sawtell; R L Thompson
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.